Research & Development
US FDA ApprovesIND for a Clinical Trial Exploring Treatment of Social Anxiety Disorder
2 December 2022 - - US-based biopharmaceutical company Ananda Scientific Inc has received approval by the US Food and Drug Administration of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol in Ananda's proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder, the company said.

The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine.

The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine.

This double-blind placebo-controlled trial will study Nantheia A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test induced Anxiety and impact on a neuroimaging biomarker.

Ananda is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA).

The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems Ltd, in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.